Impedimed (IPD)

Impedimed (IPD.AX)

Indicator:

COMMODITY CHANNEL INDEX

BULLISH CROSSOVER

Impedimed (ASX:IPD) current price has driven Commodity Channel Index to become oversold signalling the start of bullish trading conditions. Currently, the CCI is 10. During the quarter, the lowest CCI value was -195. The last oversold signal occurred on Oct 16 2018

A bullish crossover has been confirmed due the last trading session with is a strong indication of a diretional change. This indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.

The Commodity Channel Index indicator takes a security’s change in price and compares that to its average change in price. CCIs calculation produces positive and negative values that oscillate above and below a Zero Line. Typically a value of 100 is identified as overbought and a reading of -100 is identified as being oversold.

Calculation: 20 Period CCI:
1) CCI = (Typical Price - 20 Period SMA of TP) / (.015 x Mean Deviation);
2) Typical Price (TP) = (High + Low + Close)/3;

PROFILE: Impedimed (IPD.AX)

Stock Exchange: ASX
Company: Impedimed
Ticker Codes: | IPD.AX | ASX:IPD |

ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.